Integrated Filing — IndAS



General information about company

Scrip Code 544645
NSE Symbol PARKHOSPS
MSEI Symbol NOTLISTED
ISIN INE119201023
Name of company PARK MEDI WORLD LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 13-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Healthcare Services
Start date and time of board meeting 13-11-2026   09:30:00
End date and time of board meeting 13-11-2026   11:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 51,102.50 98,673.40
Other income 962.80 1,727.50
Total income 52,065.30 1,00,400.90
2 Expenses
(a) Cost of materials consumed 11,641.70 19,354.10
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (9.80) (96.50)
(d) Employee benefit expense 10,021.80 19,262.50
(e) Finance costs 1,407.70 2,388.70
(f) Depreciation, depletion and amortisation expense 2,086.00 3,970.00
(f) Other Expenses
1 Professional & Consultancy Expense 7,024.40 14,584.90
2 Other Expenses 12,252.20 22,787.40
Total other expenses 19,276.60 37,372.30
Total expenses 44,424.00 82,251.10
3 Total profit before exceptional items and tax 7,641.30 18,149.80
4 Exceptional items 0.00 0.00
5 Total profit before tax 7,641.30 18,149.80
6 Tax expense
7 Current tax 1,793.40 4,415.40
8 Deferred tax 402.20 (562.50)
9 Total tax expenses 2,195.60 3,852.90
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 5,445.70 14,296.90
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 5,445.70 14,296.90
17 Other comprehensive income net of taxes 56.50 (7.80)
18 Total Comprehensive Income for the period 5,502.20 14,289.10
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 5,218.90 13,340.70
Total profit or loss, attributable to non-controlling interests 226.80 956.20
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 5,269.10 13,327.70
Total comprehensive income for the period attributable to owners of parent non-controlling interests 233.10 961.40
21 Details of equity share capital
Paid-up equity share capital 8,638.60 8,638.60
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.26 3.31
Diluted earnings (loss) per share from continuing operations 1.26 3.31
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.26 3.31
Diluted earnings (loss) per share from continuing and discontinued operations 1.26 3.31
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the unaudited Consolidated financial results for the quarter and half year ended September 30, 2026 1. The unaudited Consolidated financial results of Park Medi World Limited (‘the Company’) for the quarter and half year ended September 30, 2026, were reviewed by the Audit committee on November 13, 2026, and approved by the Board of Directors at its meeting held on November 13, 2026, in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations), and have been subjected to limited review by the statutory auditors of the Company who have issued an unmodified opinion on the same. 2. The aforesaid unaudited Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) - 34 “Interim Financial Reporting” notified under Section 133 of the Companies Act, 2013 (“the Act”) read with the Companies (Indian Accounting Standard Rules), 2015 (as amended from time to time) and other accounting principles generally accepted in India and in terms of Regulation 33 of the Listing Regulations. 3. During the quarter: i. The Company has successfully acquired 80% shareholding of V3 Healthcare Private Limited on July 31, 2026 which operates a multi-super speciality Hospital in the name of “The Medicity Hospital’, Rudrapur, Uttarakhand, having capacity of 330 beds. Remaining 20% will be acquired by April 30, 2030. Overall cost of acquisition is approx. Rs. 1,628.40 millions with proximate valuation from a Register Valuer. Consequent to this acquisition, V3 Healthcare Private Limited has become a subsidiary of the Company. Further, the Hospital has been launched on August 2, 2026 under current management. ii. The Company has incorporated a wholly owned subsidiary in the name of Park Medicity Prayagraj Limited on September 08, 2026. This entity is for the development and operation of a 550 bed multi super-speciality hospital in Prayagraj, Uttar Pradesh. This hospital has been awarded to the Company under the Public-Private Relationship (PPP) model by the Prayagraj Municipal Corporation, Uttar Pradesh. iii. Aggarwal Hospital and Research Services Private Limited a wholly owned subsidiary of the Company has entered into operation and management agreement with Axis Educational Society (AES) for operating and managing a 300 bed multi-super speciality hospital, namely Axis Hospital and Research Centre located in Kanpur, Uttar Pradesh, for a term of 28 years w.e.f April 01, 2027. iv. The Company in its Board Meeting held on August 03, 2026 has approved the proposal to acquire 100% stake in Mehar Mediserve LLP by December 03, 2026. The LLP owns Mehar Hospital located at Zirakpur, Punjab. Mehar Hospital is a well-established multi super speciality institution with a capacity of 150+ beds. 4. Post closure of the reporting period, some of the premises inter-alia related to the Company, some of its subsidiaries and officials of the Company, were subject to search or survey by the Income Tax Department from October 12, 2026 to October 17, 2026. There has been no impact on our operations, commitments and expansion plans. 5. The Group's business activity primarily falls within a single reportable business segment namely Healthcare Service and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind AS 108- Segment Reporting. The Group does not distinguish revenues, costs and expenses between segments in its internal reporting, and report costs and expenses by nature as a whole. The Board of Directors (Chief Operating Decision Maker (CODM) reviews the Consolidated Financial information when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group operates and manages its business as a single segment mainly through the sale of healthcare services. The Group operates in one geographic segment namely within India and hence no separate information for geographic segment wise disclosure is required. 6. The allocation of the IPO proceeds was revised pursuant to Special Resolution passed by the members of the Company on September 03, 2026, through Postal Ballot. As on the September 30, 2026, the IPO proceeds have been fully utilised as summarised below along-with revised allocations: (Amount in INR Millions) 1) Object of the issue - Repayment/ prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries Details of Variation - NA Allocated amount - 3,800 Revised Allocated Amount - NA Utilised upto September 30, 2026 - 3,800 2) Object of the issue - Funding capital expenditure for development of new hospital by our Subsidiary Park Medicity (NCR) Private Limited Details of Variation - Unutilized amount of INR 409.81 million allocated to object 5 Allocated amount - 605.00 Revised Allocated Amount - 195.19 Utilised upto September 30, 2026 - 195.19 3) Object of the issue - Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens Healthcare Private Limited and Ratnagiri Innovations Private Limited Details of Variation - Unutilized amount of INR 238.51 million allocated to object 5 Allocated amount - 274.59 Revised Allocated Amount - 36.08 Utilised upto September 30, 2026 - 36.08 4) Object of the issue - Unidentified inorganic acquisitions and general corporate purposes Details of Variation - NA Allocated amount - 2,453.18 Revised Allocated Amount - NA Utilised upto September 30, 2026 - 2,453.18 5)Object of the issue - Funding capital expenditure regarding the acquisition of the Medicity Hospital, Rudrapur Details of Variation - Unutilised amount of objects 2 & 3 allocated to object 5 Allocated amount - Nil Revised Allocated Amount - 648.32 Utilised upto September 30, 2026 - 648.32 7. During the quarter ended September 30, 2026, the Company did not receive any investor complaint. No complaints were pending for resolution as on September 30, 2026. The Company has adequate systems and processes in place to address investor grievances in a timely manner in compliance with Regulation 13 of the Listing Regulations. 8. Previous period figures have been regrouped / reclassified wherever necessary to conform to current period classification and rounding off errors have been ignored. 9. The unaudited Consolidated financial results for the quarter ended September 30, 2026, are available on the Company's website at www.parkhospital.in and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com, where the shares of the Company are listed.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 1,09,871.60
Capital work-in-progress 2,329.90
Investment property
Goodwill 42,472.70
Other intangible assets 123.00
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 8.60
Trade receivables, non-current
Loans, non-current 6,820.30
Other non-current financial assets
1 Other Financial Assets 13,332.00
Total of other non-current financial assets 13,332.00
Total non-current financial assets 20,160.90
Deferred tax assets (net) 3,217.00
Other non-current assets
1 Other non-current assets 625.90
2 Non-current tax assets 7,137.10
3 Right-of-use assets 8,220.20
Total of other non-current assets 15,983.20
Total non-current assets 1,94,158.30
2 Current assets
Inventories 434.50
Current financial asset
Current investments 0.00
Trade receivables, current 87,100.30
Cash and cash equivalents 7,622.30
Bank balance other than cash and cash equivalents 19,528.30
Loans, current 0.00
Other current financial assets
Total of other current financial assets 7,213.70
Total current financial assets 1,21,464.60
Current tax assets (net)
Other current assets
1 Other current assets 5,052.00
Total of other current assets 5,052.00
Total current assets 1,26,951.10
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 3,21,109.40
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 8,638.60
Other equity 2,07,281.10
Total equity attributable to owners of parent 2,15,919.70
Non controlling interest 12,586.90
Total equity 2,28,506.60
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 17,791.30
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 9,159.10
Total of other non-current financial liabilities 9,159.10
Total non-current financial liabilities 26,950.40
Provisions, non-current 1,713.70
Deferred tax liabilities (net) 1,439.40
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 30,103.50
Current liabilities
Current financial liabilities
Borrowings, current 27,917.10
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,365.50
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 5,412.80
Total Trade payable 6,778.30
Other current financial liabilities
1 Lease Liability 304.80
2 Other current financial liabilities 15,862.60
Total of other current financial liabilities 16,167.40
Total current financial liabilities 50,862.80
Other current liabilities 1,129.40
1 Other current liabilities 1,129.40
Total of other current liabilities 1,129.40
Provisions, current 8,616.70
Current tax liabilities (Net) 1,890.40
Deferred government grants, Current 0.00
Total current liabilities 62,499.30
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 92,602.80
Total equity and liabilites 3,21,109.40
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of Employee defined benefit plans 75.50 (10.40)
Total Amount of items that will not be reclassified to profit and loss 75.50 (10.40)
2 Income tax relating to items that will not be reclassified to profit or loss 19.00 (2.60)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 56.50 (7.80)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 18,149.80
Adjustments for reconcile profit (loss)
Adjustments for finance costs 2,388.70
Adjustments for decrease (increase) in inventories (96.50)
Adjustments for decrease (increase) in trade receivables, current (27,170.20)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 369.10
Adjustments for decrease (increase) in other non-current assets (2,064.60)
Adjustments for other financial assets, non-current (4,199.00)
Adjustments for other financial assets, current (1,826.10)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (4,415.10)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (720.20)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 3,970.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (36.00)
Adjustments for provisions, non-current 1,154.10
Adjustments for other financial liabilities, current (231.80)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 1,209.60
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (36.40)
Other adjustments to reconcile profit (loss) (75.20)
Other adjustments for non-cash items 60.50
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (34,138.30)
Net cash flows from (used in) operations (15,988.50)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 4,046.40
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (20,034.90)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 11,344.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 5,989.00
Proceeds from sales of investment property 0.00
Purchase of investment property 51.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 1,645.80
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 1,327.10
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 1,977.40
Net cash flows from (used in) investing activities (15,725.30)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 21,276.60
Repayments of borrowings 0.00
Payments of lease liabilities 154.30
Dividends paid 0.00
Interest paid 1,729.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 19,393.30
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (16,366.90)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (16,366.90)
Cash and cash equivalents cash flow statement at beginning of period 23,989.30
Cash and cash equivalents cash flow statement at end of period 7,622.40